## Edgar Filing: BRAINSTORM CELL THERAPEUTICS INC. - Form 4

BRAINSTORM CELL THE Form 4	ERAPEUT	ICS INC	2.						
August 19, 2014 FORM 4	) STATES	SECU	DITIES A		сна	NCF	COMMISSION	- .T	PPROVAL
Check this box	<b>STATES</b>		ishington,			IIIGE		Number:	3235-0287 January 31,
if no longer subject to Section 16. Form 4 or		<b>CHANGES IN BENEFICIAL OWNERSHIP OF</b> <b>SECURITIES</b> ection 16(a) of the Securities Exchange Act of 1934,						Expires: 200 Estimated average burden hours per response 0.	
abligations	7(a) of the 1	Public U		ding Cor	npan	y Act	of 1935 or Section	on	
(Print or Type Responses)									
1. Name and Address of Reportin ARBEL IRIT	2. Issuer Name <b>and</b> Ticker or Trading Symbol BRAINSTORM CELL THERAPEUTICS INC. [BCLI]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) (First) C/O BRAINSTORM CELL THERAPEUTICS INC.,, 60 THIRD AVENUE, 34TH F	05		of Earliest Tr Day/Year) 2014	ransaction			X Director Officer (giv below)		% Owner her (specify
(Street) NEW YORK,, NY 10158			endment, Da onth/Day/Yea	-	1				erson
(City) (State)	(Zip)	Tab	ole I - Non-I	Derivative	Secu	rities A	Person .cquired, Disposed (	of. or Beneficia	lly Owned
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)		3. 4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5) (A) or Code V Amount (D) Price			r ) 5)	5. Amount of Securities Beneficially Owned		7. Nature of Indirect	
Reminder: Report on a separate lii	ne for each cl	ass of sec					or indirectly.		

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount Underlying Securitie (Instr. 3 and 4)		
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amou Numb Shares	
Stock Option (right to buy)	\$ 0.05	08/15/2014		A	380,000	09/15/2014 <u>(1)</u>	08/15/2024	Common Stock	380,0	
Reporting Owners										

## Edgar Filing: BRAINSTORM CELL THERAPEUTICS INC. - Form 4

Reporting Owner Name / Address		Relationships				
			10% Owner	Officer	Other	
ARBEL IRIT C/O BRAINSTORM CELL THERAPEUTICS INC., 605 THIRD AVENUE, 34TH FLOOR NEW YORK,, NY 10158		Х				
Signatures						
/s/ Irit Arbel	08/19/2014					

\*\*Signature of Reporting Person

Ś

Date

## **Explanation of Responses:**

If the form is filed by more than one reporting person, *see* Instruction 4(b)(v). \*

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Option vests and becomes exercisable in 12 consecutive, equal monthly installments commencing on September 15, 2014 until fully

(1) vested and exercisable on the first anniversary of the date of grant, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.